ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

datopotamab deruxtecan

Also written as “Dato-DXd”, “Datopotamab deruxtecan” and “Datopotamab Deruxtecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Triple Negative Breast Neoplasms · Endometrial Neoplasms · Urinary Bladder Neoplasms, led by 2 companies.

Drug pageDatopotamab deruxtecan: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 4, 202129 company-led studies, 28 open or runningCo-development: Daiichi Sankyo and AstraZeneca, Jul 2020Next primary completion: Jan 11, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca2121 open or runningphase 3since Oct 4, 2021Oct 25, 2018Jan 11, 2027phase 3 · NCT06417814
Daiichi Sankyoits history only87 open or runningphase 3since Nov 19, 2020Jan 9, 2018Jan 1, 2028phase 1 · NCT03401385

Also a collaborator on its studies: Merck and Parexel.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 6 earlier studies, Oct 25, 2018 to Apr 19, 2022.

  1. Dec 9, 2019Named datopotamab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 122
  2. Jul 27, 2020AstraZeneca develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Daiichi Sankyo and AstraZeneca (release)
  3. Jun 8, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05460273 · 119 enrolled · China
  4. Jul 21, 2022Phase 2 study in Endometrial NeoplasmsNCT05489211 · 454 planned · United States, Canada, China and more
  5. Nov 4, 2022Phase 3 study in Breast NeoplasmsNCT05629585 · 1,174 enrolled · United States, Belgium, Brazil and more
  6. Dec 28, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05687266 · 1,350 enrolled · United States, Austria, Brazil and more
  7. Oct 12, 20232 phase 3 studies in Breast NeoplasmsNCT06112379, NCT06103864
  8. Apr 2, 20242 phase 3 studies in Carcinoma, Non-Small-Cell LungNCT06350097, NCT06357533
  9. May 13, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06417814 · 768 enrolled · United States, Australia, Belgium and more
  10. Aug 7, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06564844 · 25 enrolled · United States, Brazil, Canada and more
  11. Jul 4, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07098338 · 278 planned · United States, Australia, Canada and more
  12. Sep 11, 2025Phase 3 study in Breast NeoplasmsNCT07205822 · 100 planned · United States, China, France and more
  13. Oct 28, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07291037 · 400 planned · United States, Australia, Austria and more
  14. Jun 10, 2026Phase 3 study in Carcinoma, Transitional CellNCT07720284 · 915 planned · United States, Australia, Brazil and more
  15. Sep 3, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07941609 · 250 planned · United States, Argentina, Australia and more
  16. Oct 15, 2026Primary completion moved from 2026-09-30 to 2027-01-11Date moved laterphase 3 · +3 months · NCT06417814

Ahead

  1. Jan 11, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06417814
  2. Jul 28, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06103864
  3. Sep 1, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05629585
  4. Oct 1, 2027Primary completion: phase 2 study in Endometrial NeoplasmsNCT05489211

TargetBeta

TACSTD2 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) ”NCIt, by rule
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
sacituzumab tirumotecanMerckphase 350
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 21 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07941609Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2Not yet recruitingDec 16, 2028250
NCT07720284Carcinoma, Transitional Cell · United States, Australia, Brazil and more3RecruitingSep 11, 2030915
NCT07291037Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3RecruitingJan 29, 2029400
NCT07205822Breast Neoplasms · United States, China, France and more3RecruitingFeb 2, 2028100
NCT07098338Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2RecruitingApr 6, 2029278
NCT06564844Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more3Active, not recruitingJul 10, 202625
NCT06417814Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3Active, not recruitingJan 11, 2027768
NCT06357533Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3RecruitingDec 28, 2029675
NCT06350097Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3RecruitingMar 21, 2028582
NCT06103864Breast Neoplasms · United States, Argentina, Australia and more3RecruitingJul 28, 2027625
NCT06112379Breast Neoplasms · United States, Australia, Austria and more3Active, not recruitingNov 20, 20281,902
NCT05687266Carcinoma, Non-Small-Cell Lung · United States, Austria, Brazil and more3Active, not recruitingNov 1, 20271,350
NCT05629585Breast Neoplasms · United States, Belgium, Brazil and more3Active, not recruitingSep 1, 20271,174
NCT05489211Endometrial Neoplasms · United States, Canada, China and more2RecruitingOct 1, 2027454
NCT05460273Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingNov 7, 2023119
NCT05374512Breast Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingAug 25, 2025644
NCT05104866Breast Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingJul 24, 2024732
NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2RecruitingMay 28, 2030630
NCT04612751Carcinoma, Non-Small-Cell Lung · United States, Belgium, Italy and more1Active, not recruitingMay 4, 2026155
NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more2Active, not recruitingMay 6, 2025247
NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more2Active, not recruitingNov 29, 2024243

How it is read

Names in the registry

  • “Dato-DXd”, 13 entries
  • “Datopotamab deruxtecan”, 5 entries
  • “Datopotamab Deruxtecan”, 5 entries
  • “Datopotamab deruxtecan (Dato-DXd)”, 2 entries
  • “Datopotamab Deruxtecan (Dato-DXd)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.